ScholarIQanswers from OpenAlex & ORCID
Sarayut Lucien Geater
ResearcherPublications, citations & collaboration network
Sarayut Lucien Geater is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Sarayut Lucien Geater have?
ScholarIQindexed works
Sarayut Lucien Geater has 148 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Sarayut Lucien Geater have?
ScholarIQcitation count
Sarayut Lucien Geater has 22,326 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Sarayut Lucien Geater?
ScholarIQh-index
Sarayut Lucien Geater has an h-index of 36 in OpenAlex.
What is the i10-index of Sarayut Lucien Geater?
ScholarIQi10-index
Sarayut Lucien Geater has an i10-index of 67 in OpenAlex.
What is the ORCID of Sarayut Lucien Geater?
ScholarIQorcid
The ORCID for Sarayut Lucien Geater is on the source record.
What is the OpenAlex record for Sarayut Lucien Geater?
ScholarIQopenalex
The OpenAlex for Sarayut Lucien Geater is on the source record.
What are the most-cited papers on Sarayut Lucien Geater?
ScholarIQmost cited works
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi‐Long Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong‐Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth J. O’Byrne, Jifeng Feng, Shun Lü, Yunchao Huang, Sarayut Lucien Geater, Kye Young Lee, Chun-Ming Tsai, В. А. Горбунова, Vera Hirsh, Jaafar Bennouna, С. В. Орлов, Tony Mok, Michael Boyer, Wu‐Chou Su, Ki Hyeong Lee, Terufumi Kato, Dan Massey, Mehdi Shahidi, Victoria Zazulina, Lecia V. Sequist
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari, Yi‐Long Wu, Luis Paz‐Ares, Juergen Wolf, Sarayut Lucien Geater, С. В. Орлов, Diego Cortinovis, Chong‐Jen Yu, Maximillian Hochmair, Alexis B. Cortot, Chun‐Ming Tsai, Denis Moro‐Sibilot, Rosario García Campelo, Tracey McCulloch, Paramita Sen, Margaret Dugan, Serafino Pantano, Fabrice Branle, Cristian Massacesi, Gilberto de Castro